Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1649 1674 1675
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18008324 | ACVR1 (ALK2) RECEPTOR INHIBITION TO TREAT NEUROLOGICAL DISEASES | Final Rejection | The Regents of the University of California |
| 17998057 | ENGINEERED RELAXINS AND METHODS OF USE THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 17554713 | Anti-CGRP Antibody Formulation | Non-Final OA | Eli Lilly and Company |
| 18177566 | COMPOSITIONS AND METHODS FOR CROSSING BLOOD BRAIN BARRIER | Non-Final OA | California Institute of Technology |
| 18645005 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18283665 | ANTIBODY OR FRAGMENT THEREOF, AND METHOD FOR USING SAME | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 17628132 | ADHESIVE PROTEIN | Non-Final OA | National University Corporation Tokai National Higher Education and Research System |
| 17490409 | FSH LOWERING AGENT OR ACTIVIN PATHWAY MODIFYING AGENT TO TREAT INFERTILITY IN FEMALES | Non-Final OA | University Of Cincinnati |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy